Antibiotics use patterns in end-of-life cancer patients and medical staff’s perception of antimicrobial stewardship programs
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: While most cancer patients with end-of-life (EOL) care receive antibiotic treatments, antibiotic use should be decided appropriately considering the benefits, side effects, resistance, and cost effects. Antimicrobial stewardship programs (ASP) are important for patients with EOL care, but there is limited study analyzing actual antibiotic use in EOL care and the perceptions of Korean medical staff. Methods: Electronic medical records of 149 deceased cancer patients hospitalized in the medical hospitalist units at Asan Medical Center in Seoul from May 2019 to September 2021 were reviewed. Basic information, antibiotic use, duration, and changes were investigated. We surveyed medical staff’s perceptions of antibiotics in cancer patients with EOL. Results: Of the 149 cancer patients with EOL care, 146 (98.0%) agreed with physician orders for life-sustaining treatment (POLST). In total, 143 (95.9%) received antibiotics, 110 (76.9%) received combination antibiotic treatment, and 116 (81.1%) were given antibiotics until the day of death. In a survey of 60 medical staff, 42 (70.0%) did not know about ASP, and 24 (40.0%) thought ASP was important in EOL care. Nineteen doctors (31.7%) discussed the use or discontinuation of antibiotics with patients or caregivers when writing POLST, but only 8 patients (5.6%) stopped antibiotics after POLST. Conclusions: Most cancer patients with EOL care continue to receive antibiotics until just before their death. A careful approach is needed, considering the benefits and side effects of antibiotic use, and the patient’s right to self-decision. It is necessary to actively improve awareness of ASP and its importance for medical staff.
Abstract
Background/Aims: While most cancer patients with end-of-life (EOL) care receive antibiotic treatments, antibiotic use should be decided appropriately considering the benefits, side effects, resistance, and cost effects. Antimicrobial stewardship programs (ASP) are important for patients with EOL care, but there is limited study analyzing actual antibiotic use in EOL care and the perceptions of Korean medical staff. Methods: Electronic medical records of 149 deceased cancer patients hospitalized in the medical hospitalist units at Asan Medical Center in Seoul from May 2019 to September 2021 were reviewed. Basic information, antibiotic use, duration, and changes were investigated. We surveyed medical staff’s perceptions of antibiotics in cancer patients with EOL. Results: Of the 149 cancer patients with EOL care, 146 (98.0%) agreed with physician orders for life-sustaining treatment (POLST). In total, 143 (95.9%) received antibiotics, 110 (76.9%) received combination antibiotic treatment, and 116 (81.1%) were given antibiotics until the day of death. In a survey of 60 medical staff, 42 (70.0%) did not know about ASP, and 24 (40.0%) thought ASP was important in EOL care. Nineteen doctors (31.7%) discussed the use or discontinuation of antibiotics with patients or caregivers when writing POLST, but only 8 patients (5.6%) stopped antibiotics after POLST. Conclusions: Most cancer patients with EOL care continue to receive antibiotics until just before their death. A careful approach is needed, considering the benefits and side effects of antibiotic use, and the patient’s right to self-decision. It is necessary to actively improve awareness of ASP and its importance for medical staff.
참고문헌 (30)
- Oh DY, "Antibiotic use during the last days of life in cancer patients", Eur J Cancer Care(Engl), 15, pp.74~79 (2006)
- Thompson AJ, "Antimicrobial use at the end of life among hospitalized patients with advanced cancer", Am J Hosp Palliat Care, 29, pp.599~603 (2012)
- Kates OS, "Association of physician orders for life-sustaining treatment with inpatient antimicrobial use at end of life in patients with cancer", Open Forum Infect Dis, 8, pp.ofab361~ (2021)
- Crispim DH, "End-of-life use of antibiotics : a survey on how doctors decide", Int J Infect Dis, 114, pp.219~225 (2022)
- Gaw CE, "Physician perceptions regarding antimicrobial use in end-of-life care", Infect Control Hosp Epidemiol, 39, pp.383~390 (2018)
- 권기태, "Implementation of Antimicrobial Stewardship Programs in End-of-Life Care", Infection and Chemotherapy, 51(2), pp.89~97 (2019), 대한감염학회[DOI]
- Barlam TF, "Implementing an antibiotic stewardship program : guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America", Clin Infect Dis, 62, pp.e51~e77 (2016)
- Kim D, "Use of antimicrobial agents in actively dying inpatients after suspension of life-sustaining treatments : Suggestion for antimicrobial stewardship", J Microbiol Immunol Infect, 55, pp.651~661 (2022)
- 위유미, "Use of Antibiotics Within the Last 14 Days of Life in Korean Patients: A Nationwide Study", Journal of Korean Medical Science, 38(9), pp.1~10 (2023), 대한의학회[DOI]
- 이상민, "말기와 임종과정에 대한 정의 및 의학적 판단지침", 대한의사협회지, 61(8), pp.509~521 (2018), 대한의사협회[DOI]
- Gonzalez L, "Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients", Crit Care, 17, pp.R140~ (2013)
- Reinbolt RE, "Symptomatic treatment of infections in patients with advanced cancer receiving hospice care", J Pain Symptom Manage, 30, pp.175~182 (2005)
- Nakagawa S, "Can anti-infective drugs improve the infection-related symptoms of patients with cancer during the terminal stages of their lives?", J Palliat Med, 13, pp.535~540 (2010)
- Hung KC, "Antibiotic stewardship program(ASP)in palliative care : antibiotics, to give or not to give", Eur J Clin Microbiol Infect Dis, 41, pp.29~36 (2022)
- Opal SM, "Antibiotic usage and resistance : gaining or losing ground on infections in critically ill patients?", JAMA, 302, pp.2367~2368 (2009)
- Spellberg B, "The epidemic of antibiotic-resistant infections:a call to action for the medical community from the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.155~164 (2008)
- Levin PD, "End-of-life treatment and bacterial antibiotic resistance : a potential association", Chest, 138, pp.588~594 (2010)
- Kwak YG, "Frequent Prescription of antibiotics and high burden of antibiotic resistance among deceased patients in general medical wards of acute care hospitals in Korea", PLoS One, 11, pp.e0146852~ (2016)
- Lessa FC, "Burden of Clostridium difficile infection in the United States", N Engl J Med, 372, pp.825~834 (2015)
- Zhang S, "Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study", BMC Infect Dis, 16, pp.447~ (2016)
- Kimura T, "Excess length of hospital stay, mortality and cost attributable to Clostridioides(Clostridium)difficile infection and recurrence : a nationwide analysis in Japan", Epidemiol Infect, 148, pp.e65~ (2020)
- Lv L, "The incidence and risk of infusion phlebitis with peripheral intravenous catheters : a meta-analysis", J Vasc Access, 21, pp.342~349 (2020)
- Rupp ME, "Intravascular catheter-related bloodstream infections", Infect Dis Clin North Am, 32, pp.765~787 (2018)
- Gahlot R, "Catheter-related bloodstream infections", Int J Crit Illn Inj Sci, 4, pp.162~167 (2014)
- Cunha BA, "Antibiotic side effects", Med Clin North Am, 85, pp.149~185 (2001)
- Dilley M, "Immediate and delayed hypersensitivity reactions to antibiotics : aminoglycosides, clindamycin, linezolid, and metronidazole", Clin Rev Allergy Immunol, 62, pp.463~475 (2022)
- Minaldi E, "Immediate and delayed hypersensitivity reactions to beta-lactam antibiotics", Clin Rev Allergy Immunol, 62, pp.449~462 (2022)
- Oizumi K, "Clinical study of drug fever induced by parenteral administration of antibiotics", Tohoku J Exp Med, 159, pp.45~56 (1989)
- Morioka S, "Determinants of physicians’ attitudes toward the management of infectious diseases in terminally Ill patients with cancer", J Pain Symptom Manage, 60, pp.1109~1116 (2020)
- 김연주, "연명의료결정법 전후 전공의들의 연명의료법에 대한 인지도 및 시행 경험, 그리고 현장에서 겪는 어려움", 한국의료윤리학회지, 23(4), pp.279~299 (2020), 한국의료윤리학회[DOI]